9 February 2016

Hydrodec hails transformer deal

Robert Tyerman

Profitability is now in sight claims 'green' oil technology hopeful Hydrodec following a bulk order for its 'Superfine' transformer oil.

AIM-quoted Hydrodec, set up to commercialise Australian technology to remove harmful contaminants in oil refining, says written acceptance from a major transformer manufacturer Down Under and conditional acceptance from another for bulk use of Superfine could ensure a firm market for at least half the capacity of Hydrodec's newly-commissioned refining plant in New South Wales. That, says the company, should generate annual revenues of £1.8 million, underpinned by feedstock supply commitments from major utilities.

John Gunn, the former City tycoon-turned young company backer who chairs Hydrodec, says the company, which lost nearly £6 million last year, will now be 'cash-flow positive next month and profitable in the fourth quarter'. The New South Wales plant is 'on time, and under budget' and should reach 80 per cent capacity by the end of the year and hit its full 20,000-litres-a-day potential by the first quarter of 2007.

He says the contracts 'go on', without a set termination date, and argues that Superfine faces a 'virtuous circle'. It is 'very "green" and self-sustaining': once used or filtered, it can be re-used and re-refined and 'we will refresh it and give it back over the long term.

'We have done the tests', explains Gunn, 'and the product comes up better than new after this process, with even less sulphur second time round'. With a management team boasting senior experience at chemical giants Dow , Du Pont and ICI, he says Hydrodec now intends to build a new plant and is weighing whether to site it in the USA, Japan, Turkey or Germany.

Gunn insists Hydrodec, which ended last year with £3.3 million cash and put a value of £7.3 million on its patented technology, is not looking for joint venture partners. 'We will need no new money until we have to build the new plant', he asserts.

At 28.75p, Hydrodec is a long-term gamble, which could pay off handsomely if present hopes are realised.

Growth Company Investor’s award-winning team offer outstanding share recommendation performance. Get immediate access to all these recommendations – click here.

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Forbidden focuses on selling

Forbidden Technologies (AIM: FBT) has been around a long time but has failed to generate much in the way of revenues, despite having a product that sounds like it should be a winner. There were board changes last year and new CEO Aziz Musa is shifting resources towards selling and away from technological development. This has to be the right strategy and we should find out if it’s working as this year unfolds.

Wash those nits right out of your hair!

Tyratech (AIM: TYRU) offers a compelling product proposition. Controlling bugs and parasites using conventional pesticides is both harmful to the environment and ineffective. Over the years insects have built up resistance to many of the chemicals used to kill them. So Tyratech’s natural products are not only safer but also a lot more effective than the competition. 

Angling for a cancer breakthrough

Results from medical device manufacturer Angle (AIM: AGL) showed its innovative Parsortix system to be nicely on track. The first commercial sales for research use have just been made and three leading cancer centres are moving forward with trials that will support its clinical use in the diagnosis of ovarian cancer.

2016 Quoted Company Award Winners announced

The 12th annual Grant Thornton Quoted Company Awards took place this week at the Natural History Museum in London. This prestigious event is organised by Growth Company Investor and is a celebration of the success and achievements of the UK’s smaller company sector. We published the shortlisted nominees for each award category earlier in January; so read on to see who the winners were...

Plexus hammered by oil industry shutdown

In the middle of 2014 Plexus (AIM: POS) was riding high with a share price of 320p giving the company a market value of £270 million. Today’s profit warning has seen the shares slump 40 per cent to just 73p, valuing Plexus at a mere £65 million. As an engineering company selling mainly into the oil industry, we shouldn’t be too surprised by downgrades. But the severity is startling.

Fusionex shares plunge on hidden profit warning

Malaysian big data software specialist Fusionex (AIM: FXI) has released an upbeat results statement for the year to September. As well as beating historic forecasts, the new financial year is said to have started “on a very strong note… the outlook for 2016 and beyond is very positive”. Sounds fantastic! Yet by this afternoon the shares had collapsed by 35 per cent.

More News